- Home
- DAWN vs AGL Comparison
DAWN vs AGL Comparison
Compare DAWN & AGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- AGL
- Stock Information
- Founded
- DAWN 2018
- AGL 2016
- Country
- DAWN United States
- AGL United States
- Employees
- DAWN N/A
- AGL N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- AGL Managed Health Care
- Sector
- DAWN Health Care
- AGL Health Care
- Exchange
- DAWN Nasdaq
- AGL Nasdaq
- Market Cap
- DAWN 1.2B
- AGL 1.4B
- IPO Year
- DAWN 2021
- AGL 2021
- Fundamental
- Price
- DAWN $12.43
- AGL $3.53
- Analyst Decision
- DAWN Strong Buy
- AGL Hold
- Analyst Count
- DAWN 7
- AGL 18
- Target Price
- DAWN $36.17
- AGL $4.03
- AVG Volume (30 Days)
- DAWN 782.5K
- AGL 5.0M
- Earning Date
- DAWN 02-25-2025
- AGL 02-25-2025
- Dividend Yield
- DAWN N/A
- AGL N/A
- EPS Growth
- DAWN N/A
- AGL N/A
- EPS
- DAWN N/A
- AGL N/A
- Revenue
- DAWN $101,953,000.00
- AGL $5,594,117,000.00
- Revenue This Year
- DAWN N/A
- AGL $41.67
- Revenue Next Year
- DAWN $35.37
- AGL $8.85
- P/E Ratio
- DAWN N/A
- AGL N/A
- Revenue Growth
- DAWN N/A
- AGL 54.10
- 52 Week Low
- DAWN $11.13
- AGL $1.50
- 52 Week High
- DAWN $18.07
- AGL $7.73
- Technical
- Relative Strength Index (RSI)
- DAWN 52.15
- AGL 59.38
- Support Level
- DAWN $11.65
- AGL $3.32
- Resistance Level
- DAWN $12.54
- AGL $3.73
- Average True Range (ATR)
- DAWN 0.47
- AGL 0.24
- MACD
- DAWN 0.02
- AGL -0.03
- Stochastic Oscillator
- DAWN 80.53
- AGL 54.40
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.
About AGL agilon health inc.
Agilon Health Inc is transforming healthcare by empowering primary care physicians for the health of the patients. The company enables physicians to create their own Medicare-centric globally capitated line of business. The company derives its revenue from Medical services.